Hypertension
Conditions
Keywords
Systolic hypertension
Brief summary
The aim of this study is to evaluate the effect of lacidipine and losartan in elderly hypertensive patients on reducing the 24 hour systolic BP variability, which is one of the potential parameter to consider in treating elderly hypertensive patients.
Detailed description
In this study, we investigate the effects of two anti-hypertensive medications on systolic BP variability profile as a pilot study. This is a prospective, randomized, open-label, blinded end point (PROBE), parallel group study with two treatment arms. At the end of an initial 2-week washout period, during which any eventual anti-hypertensive drug is discontinued, patients fulfilling the inclusion criteria are randomly treated with the lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks. If the BP goal (SBP \< 140 mmHg and DBP \< 90 mmHg) has not been attained after 4 week's treatment, 12.5 mg hydrochlorothiazide (HCTS) once daily can be added. Patients are checked 24-h ambulatory BP monitoring (ABPM) at the end of the washout period and after 12 weeks of active treatment. At each visit, seated cuff SBP and DBP, heart rate, use of concomitant medication and spontaneously reported adverse events are recorded.
Interventions
DRUGlacidipine (4 mg) or losartan (50 mg)
lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
Sponsors
Seoul National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Inclusion criteria
* Elderly patients (age \> 65 years) * Essential hypertension (systolic BP \> 140 mmHg or diastolic BP \> 90 mm Hg) * Provide written informed content
Exclusion criteria
* Secondary hypertension * Myocardial infarction or cerebrovascular accident within the preceding 6 months * Clinically significant valvular heart disease, heart failure (Class III, IV), renal insufficiency (serum creatinine \> 2.5mg/dl), hepatic failure, uncontrolled diabetes mellitus * Known hypersensitivity to the drugs used in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of 24-hour, one day systolic BP standard deviation (SD) within subjects (the difference of SD before and after 12 weeks' treatment) in lacidipine group and losartan group | — |
Secondary
| Measure | Time frame |
|---|---|
| The difference of the changes in office diastolic and systolic BP after 12 weeks' treatment between lacidipine group and losartan group | — |
| The difference of the mean 24-hour ABPM systolic and diastolic BP after 12 weeks' treatment between lacidipine group and losartan group | — |
| The difference of the diastolic and systolic BP control rates after treatment between the 2 groups | — |
| The change of 24-hour, one day diastolic BP standard deviation (SD) within subjects (the difference of SD before and after 12 weeks' treatment) in lacidipine group and losartan group | — |
| The difference of the variation of coefficient (CV) of the mean values (24-hour BP SD divided by the mean multiplied by 100) between 2 groups | — |
| The difference of the smoothness index (SI, dividing the average of the 24 hourly change after treatment by the corresponding standard deviation) between 2 groups | — |
| The difference of the changes in pulse pressure after treatment between the 2 groups | — |
| The difference of the changes in 24-hour, one day BP standard deviation (SD) within subjects between lacidipine group and losartan group | — |
Countries
South Korea
Contacts
Primary ContactCheol-Ho Kim, MD, PhD
Outcome results
None listed